Real-time hydration advice from new ‘smart’ drinks bottle


Real-time hydration advice from new ‘smart’ drinks bottle Cambridge Consultants introduces i-dration – the first in a new generation of hardware smartphone apps Cambridge, UK – December 7, 2010 – Cambridge Consultants, a leading technology product design and development firm, today announced the development of the i-dration drinks bottle. The i-dration is a device that …




Continue reading

Encouraging Data on Astex’s Anti-Cancer Drug AT9283 to be Presented at ASH


New Data Suggest a Potential Role for AT9283 in Combination With Lenalidomide and With Docetaxel in the Treatment of Multiple Myeloma and Non-Hodgkin’s Lymphoma Cambridge, UK, 1st December 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, today announced presentations of new data on its combinatorial oncogenic kinase inhibitor AT9283. …




Continue reading

Mobile health device links patients and healthcare professionals anytime, anywhere


Cambridge Consultants’ Minder, powered by Vena, arms patients with a pocket-sized ‘smart’ device that can reduce recovery times and hospital visits Cambridge Consultants, a leading technology product design and development firm, today announced a new product concept based on its low-cost Continua-compliant Vena platform.  The Minder, powered by Vena, enables continuous, real-time medical data collection …




Continue reading

Cambridge is urged to dig deep for Children in Need!


Your support for the Cambridge FunRun in aid of BBC Children in Need is urgently needed now! With many local companies weathering the recession well and recruiting vigorously, you might expect that next Friday’s 1.1 mile relay race on Cambridge Science Park would have attracted generous contributions… That does not appear to be the case. …




Continue reading

Astex and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma


Cambridge, UK, 4th November 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the NCIC Clinical Trials Group in Canada, announced today the initiation of a Phase II clinical trial of Astex’s combinatorial oncogenic kinase inhibitor, AT9283, to treat patients with relapsed or refractory multiple myeloma, an incurable blood …




Continue reading

Research from Cambridge Consultants Identifies Solutions to Address Global Drug Counterfeiting Epidemic


Phony internet pharmacies and other illegitimate outlets are driving the massive counterfeit medicine market to consumers worldwide, according to a recent report released today by Cambridge Consultants.  Contributing to its findings on the serious issues relating to counterfeit medicine and the diversion of legitimate products, the leading technology product design and development firm conducted in-depth …




Continue reading